Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

Journal of the American College of Cardiology

Volumn 71, Issue 23, 2018, Pages 2628-2639

  Kosiborod, Mikhail ^a,n   Lam, Carolyn S P ^b,c,n   Kohsaka, Shun ^d,n   Kim, Dae Jung ^e,n   Karasik, Avraham ^f,n   Shaw, Jonathan ^g,n   Tangri, Navdeep ^h,n   Goh, Su Yen ^i,n   Thuresson, Marcus ^j   Chen, Hungta ^k,n   Surmont, Filip ^k,n   Hammar, Niklas ^l,m,n   Fenici, Peter ^k,n   Cavender, Matthew A ⁿ   Fu, Alex Z ⁿ   Wilding, John P ⁿ   Khunti, Kamlesh ⁿ   Norhammar, Anna ⁿ   Birkeland, Kåre ⁿ   Jørgensen, Marit Eika ⁿ   Holl, Reinhard W ⁿ   Gulseth, Hanne Løvdal ⁿ   Carstensen, Bendix ⁿ   Bollow, Esther ⁿ   Franch Nadal, Josep ⁿ   García Rodríguez, Luis Alberto ⁿ   Arnold, Suzanne ⁿ   Bodegård, Johan ⁿ   Nahrebne, Kyle ⁿ   Blak, Betina T ⁿ   Wittbrodt, Eric T ⁿ   Saathoff, Matthias ⁿ   Noguchi, Yusuke ⁿ   Tan, Donna ⁿ   Williams, Maro ⁿ   Lee, Hye Won ⁿ   Greenbloom, Maya ⁿ   Kaidanovich Beilin, Oksana ⁿ   Yeo, Khung Keong ⁿ   Bee, Yong Mong ⁿ   Khoo, Joan ⁿ   Koong, Agnes ⁿ   Lau, Yee How ⁿ   Gao, Fei ⁿ   Tan, Wee Boon ⁿ   Kadir, Hanis Abdul ⁿ   Ha, Kyoung Hwa ⁿ   Lee, Jinhee ⁿ   Chodick, Gabriel ⁿ   Melzer Cohen, Cheli ⁿ   Whitlock, Reid ⁿ   Cea Soriano, Lucia ⁿ   Fernándex Cantero, Oscar ⁿ   Riehle, Ellen ⁿ   Ilomaki, Jennie ⁿ   Magliano, Dianna ⁿ   more..

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b Singapore Health Services   (Singapore)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Ajou University School of Medicine   (South Korea)

^f TEL AVIV UNIVERSITY   (Israel)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ SINGAPORE GENERAL HOSPITAL   (Singapore)

^j STATISTICON AB   (Sweden)

^k ASTRAZENECA   (United Kingdom)

^l KAROLINSKA INSTITUTE   (Sweden)

^m ASTRAZENECA R AND D   (Sweden)

ⁿ NONE

more..

Author keywords

death; diabetes mellitus; heart failure; observational studies; SGLT 2 inhibitor; sodium glucose cotransporter 2 inhibitors

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN;

ADULT; ARTICLE; AUSTRALIA; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; EUROPE; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISRAEL; JAPAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIDDLE EAST; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGAPORE; SOUTH KOREA; UNITED STATES; AGED; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECT; ELECTRONIC HEALTH RECORD; GLUCOSE BLOOD LEVEL; INTERNATIONAL COOPERATION; METABOLISM; PHARMACOLOGY;

ADULT; AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INTERNATIONALITY; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85047499725     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.03.009     Document Type: Article

References (35)

1. Nanditha, A., Ma, R.C., Ramachandran, A., et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care 39 (2016), 472–485.
2. Abuyassin, B., Laher, I., Diabetes epidemic sweeping the Arab world. World J Diabetes 7 (2016), 165–174.
3. International Diabetes Federation. IDF Diabetes Atlas. 8th Edition, 2017, International Diabetes Federation, Brussels, Belgium.
4. Ueshima, H., Sekikawa, A., Miura, K., et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation 118 (2008), 2702–2709.
5. Woodward, M., Zhang, X., Barzi, F., et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 26 (2003), 360–366.
6. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
7. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
8. Mahaffey, K.W., Neal, B., Perkovic, V., et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137 (2018), 323–334.
9. Kosiborod, M., Cavender, M.A., Fu, A.Z., et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136 (2017), 249–259.
10. Cheol Seong, S., Kim, Y.-Y., Khang, Y.-H., et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Intern J Epidemiol 46 (2017), 799–800.
11. Lee, J., Lee, J.S., Park, S.-H., Shin, S.A., Kim, K., Cohort profile: the National Health Insurance Service–National Sample Cohort (NHIS-NSC), South Korea. International J Epidemiol, 46, 2017, e15.
12. Tanabe, M., Motonaga, R., Terawaki, Y., Nomiyama, T., Yanase, T., Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. J Diabetes Investigation 8 (2017), 227–234.
13. Tanabe, M., Nomiyama, T., Motonaga, R., Murase, K., Yanase, T., Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database. BMC Endocrine Disorders, 15, 2015, 49.
14. Urushihara, H., Taketsuna, M., Liu, Y., et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese Hospital Database. PLOS One, 7, 2012, e53224.
15. SingHealth Group. SingHealth Duke-NUS Diabetes Centre. 2014. Available at: https://www.singhealth.com.sg/PatientCare/ClinicalSpecialties/Pages/diabetes-centre.aspx Accessed February 2018.
16. National Heart Research Institute Singapore. Clinical sciences and statistics core. 2016. Available at: https://www.nhcs.com.sg/nhris/Pages/Research/ResearchCores/ClinicalSciencesandStatisticsCore.aspx Accessed February 2018.
17. Integrated Health Information Systems (IHIS). Electronic Health Intelligence System. 2018. Available at: https://www.ihis.com.sg/Project_Showcase/Healthcare_Systems/Pages/eHINTS.aspx Accessed February 2018.
18. Chodick, G., Heymann, A.D., Shalev, V., Kookia, E., The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 18 (2003), 1143–1146.
19. Heymann, A.D., Chodick, G., Halkin, H., et al. The implementation of managed care for diabetes using medical informatics in a large Preferred Provider Organization. Diabetes Res Clinical Practice 71 (2006), 290–298.
20. Shalev, V., Chodick, G., Goren, I., Silber, H., Kokia, E., Heymann, A.D., The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Internat J Cardiol 152 (2011), 345–349.
21. Australian Institute of Health and Welfare. Diabetes prevalence in Australia: an assessment of national data sources. 2009. Available at: https://www.aihw.gov.au/reports/diabetes/diabetes-prevalence-in-australia-an-assessment-of/contents/table-of-contents Accessed February 2018.
22. Harding, J.L., Shaw, J.E., Peeters, A., Cartensen, B., Magliano, D.J., Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care 38 (2015), 264–270.
23. Statistics Canada. Census Profile, 2016 Census. Manitoba [Province] and Canada [Country]. 2016. Available at: http://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/Page.cfm?Lang=E&Geo1=PR&Code1=46&Geo2=&Code2=&Data=Count&SearchText=Manitoba&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=46 Accessed February 2018.
24. Blanchard, J.F., Ludwig, S., Wajda, A., et al. Incidence and prevalence of diabetes in Manitoba, 1986-1991. Diabetes Care 19 (1996), 807–811.
25. Japanese Ministry of Health Labor and Welfare. Number of deaths and percentage distribution by place of occurrence, by year. Available at: http://www.mhlw.go.jp/english/database/db-hh/xls/1-25.xls. Accessed February 2018.
26. Registry of Births and Deaths Immigration and Checkpoints Authority Singapore. Report on registration of births and deaths. 2016. Available at: https://www.ica.gov.sg/cms/files/2016%20Annual%20RBD%20Report.pdf Accessed February 2018.
27. Williams, R.L., A Note on robust variance estimation for cluster-correlated data. Biometrics 56 (2000), 645–646.
28. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
29. Viechtbauer, W., Conducting meta-analyses in R with the metafor package. J Stat Softw, 36, 2010, 48.
30. Suissa, S., Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?. Diabetes Care 41 (2018), 6–10.
31. Birkeland, K.I., Jorgensen, M.E., Carstensen, B., et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 5 (2017), 709–717.
32. Eriksson, J.W., Bodegard, J., Nathanson, D., Thuresson, M., Nystrom, T., Norhammar, A., Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract 117 (2016), 39–47.
33. Nystrom, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., Eriksson, J.W., Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab 19 (2017), 831–841.
34. Nystrom, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., Eriksson, J.W., Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract 123 (2017), 199–208.
35. Persson, F., Nystrom, T., Jorgensen, M.E., et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab 20 (2018), 344–351.